SCHEMBL21592288

SCHEMBL21592288

Cc1oc2cc(Br)ccc2c(=O)c1CN(CCCn1ccnc1)Cc1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 7/20 0.50
▸ CYP11B2 P19099 7/20 0.50
▸ CYP19A1 P11511 4/20 0.43
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ PKM P14618 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ GSK3B P49841 2/20 0.37
▸ QPCT Q16769 2/20 0.37
▸ HMOX1 P09601 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21592272 0.88 NPC1 (0.48) CYP11B1CYP11B2CYP19A1NPC1RAB9A
SCHEMBL21592284 0.85 CYP19A1 (0.47) CYP11B1CYP11B2CYP19A1ATMMEN1
SCHEMBL21591435 0.82 CYP11B1 (0.47) CYP11B1CYP11B2CYP19A1NPC1RAB9A
SCHEMBL21592266 0.80 ALDH1A1 (0.41) CYP11B1CYP11B2CYP19A1NPC1RAB9A
SCHEMBL21591552 0.80 KCNA5 (0.41) KDM4ELMNAMEN1KMT2APKM
SCHEMBL21592248 0.78 CYP19A1 (0.46) CYP11B1CYP11B2CYP19A1NPC1RAB9A
SCHEMBL21591489 0.72 CYP11B1 (0.62) CYP11B1CYP11B2CYP19A1NPC1RAB9A
SCHEMBL21591479 0.72 CYP11B1 (0.47) CYP11B1CYP11B2CYP19A1NPC1RAB9A
SCHEMBL21591430 0.72 CYP11B1 (0.64) CYP11B1CYP11B2CYP19A1KMT2AALDH1A1
SCHEMBL21591502 0.71 CYP11B1 (0.59) CYP11B1CYP11B2CYP19A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US claimed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US claimed
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS CYP11B1 43/4885CYP11B2 50/4885CYP19A1 589/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS CYP11B1 43/4885CYP11B2 50/4885CYP19A1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback